Pfizer, Parke Davis - top therapeutic classes

07 Feb 2000

1

12-month period ended Nov 1999

Therapeutic class Sales in Rs.cr Growth %
Cough sedatives 85.5 25.2
Vitamin B complex 82.4 7.8
Tetracycline combinations 34.0 0.5
Anti-rheumatic non-steroid 30.0 19.54
Protein supplements 27.5 16.09

Parke Davis
12-month period ended Nov 1999

Therapeutic class Sales in Rs.cr Growth %
Expectorants 31.1 62.28
Antacids/antiflatulents 29.0 -8.0
Calcium 13.3 --
Chloramphenicol 11.9 -22.5
Multivitamin minus minerals 8.6 26.9

Source: IMS Health

Latest articles

Unitree powers up for Shanghai debut after record IPO demand

Unitree powers up for Shanghai debut after record IPO demand

Microsoft retreats in China, but AI boom keeps a window open

Microsoft retreats in China, but AI boom keeps a window open

Apple trains China AI model with Alibaba support for local rollout

Apple trains China AI model with Alibaba support for local rollout

Sigma Advanced to acquire UK aerospace supplier Bromford for ₹153 crore

Sigma Advanced to acquire UK aerospace supplier Bromford for ₹153 crore

Akasa Air plans ₹1,050 crore fundraising to support growth amid higher costs

Akasa Air plans ₹1,050 crore fundraising to support growth amid higher costs

AI startup Reflection signs over $1 billion computing deal with Nebius

AI startup Reflection signs over $1 billion computing deal with Nebius

Tata Power explores $450 million overseas loan for business operations

Tata Power explores $450 million overseas loan for business operations

TCS wins technology contract for New York JFK Airport’s $19 billion terminal

TCS wins technology contract for New York JFK Airport’s $19 billion terminal

South Korean firms unveil $195 billion investment in AI and advanced industries

South Korean firms unveil $195 billion investment in AI and advanced industries
View details about the software product Informachine File Manager
View details about the software product Informachine News Trackers